Glucose Laboratoire Aguettant

Glucose Laboratoire Aguettant is an intravenous solution that contains glucose monohydrate as its sole active ingredient. The product is supplied in a sterile liquid form intended for infusion into the bloodstream, providing a readily available source of glucose for cellular metabolism. It is marketed in the European Union as an over‑the‑counter (OTC) preparation, and the specific concentration or strength is not disclosed on the label.

Glucose Laboratoire Aguettant is used in clinical settings where rapid provision of an energy substrate is required.

- To correct or prevent low blood glucose levels (hypoglycemia) in patients who cannot eat or absorb carbohydrates. - As part of intravenous fluid therapy to maintain caloric intake during surgery or intensive care. - To supply glucose for patients receiving parenteral nutrition when oral intake is insufficient. - In diagnostic procedures such as glucose tolerance testing where controlled glucose administration is needed. - To support metabolic demands in patients with increased energy requirements, such as trauma or severe infection.

Adverse reactions to Glucose Laboratoire Aguettant are generally related to the intravenous administration of a carbohydrate solution.

Common: - Mild nausea or vomiting. - Transient headache or dizziness. - Local irritation at the infusion site, such as erythema or mild pain. - Temporary increase in thirst due to higher osmolality. - Slight rise in serum potassium levels.

Serious: - Hyperglycemia with markedly elevated blood glucose. - Fluid overload or pulmonary edema, especially in patients with cardiac or renal impairment. - Allergic reactions ranging from urticaria to anaphylaxis. - Electrolyte disturbances, for example hyponatremia or severe potassium shifts. - Osmotic diuresis leading to dehydration and electrolyte loss.

When using Glucose Laboratoire Aguettant, clinicians should consider several precautionary measures to ensure safe administration and to minimize risk.

- Assess blood glucose before and during infusion to avoid hyperglycemia. - Evaluate fluid status and cardiac function, especially in patients at risk of volume overload. - Use aseptic technique to prevent contamination of the intravenous solution. - Adjust infusion rate in patients with renal or hepatic impairment. - Monitor electrolytes, particularly sodium and potassium, during prolonged therapy. - Consider alternative carbohydrate sources for patients with known glucose intolerance or metabolic disorders.

Glucose Laboratoire Aguettant may interact with other medications or clinical conditions; awareness of these interactions helps guide appropriate use.

Avoid: - Concurrent administration of high‑dose insulin without glucose monitoring, which can precipitate severe hypoglycemia. - Co‑infusion with hypertonic saline solutions that could exacerbate fluid overload. - Use in patients receiving diuretics that markedly alter electrolyte balance without close monitoring.

Use with caution: - Concurrent use of potassium‑containing IV fluids, as glucose infusion can shift potassium intracellularly. - Administration alongside beta‑adrenergic agonists, which may increase glucose production and affect blood sugar control. - Patients on corticosteroids, who may have altered glucose metabolism, requiring closer glucose monitoring.